You are here: Industry Insights > Actemra/RoActemra

News List

European Commission approves Actemra/RoActemra by Roche to treat severe COVID-19 expresspharma
December 13, 2021
Approval based on results from four phase-III studies in more than 5,500 patients
EMA Expands Authorization for Roche’s Actemra/RoActemra in COVID contractpharma
December 08, 2021
An accelerated assessment by the EMA’s CHMP reviewed results from four studies of Actemra/RoActemra in over 5,500 patients with severe or critical COVID-19.
CHMP recommend approval for Roche’s COVID-19 therapy PharmaTimes
December 08, 2021
According to clinical data, Roche’s new COVID-19 treatment Actemra/RoActemra lowered mortality risk in critically ill adult patients.
EMA CHMP recommends granting approval for Roche’s therapy to treat Covid-19 Pharmaceutical-Technology
December 08, 2021
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended EU marketing authorisation for Roche’s Actemra/RoActemra (tocilizumab) to treat adult Covid-19 patients.
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19 expresspharma
December 07, 2021
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase-III studies. The European Commission is expected to make a final decision regarding approval in the near future.